{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/604630531c01c833e67e73a2/65b90fb7dfd9eb0015e93771?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Compass-studien","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/604630531c01c833e67e73a2/1706626990710-8c65f7888a22d6ec1ff73c3201071ed9.jpeg?height=200","description":"<p>För hälso- och sjukvårdspersonal. På 7 minuter får du här en sammanfattgning av Compass-studien. Vill du ha utförligare information hänvisar vi dig till att läsa studien i sin helhet, och det hittar du på denna länk:</p><p><a href=\"https://pubmed.ncbi.nlm.nih.gov/35383832/\" rel=\"noopener noreferrer\" target=\"_blank\">Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial - PubMed (nih.gov)</a></p><p><br></p><p>Musik: Tomas Täckström</p><p><br></p><h6>MA-M_FIN-SE-0213-1</h6><p><br></p>","author_name":"Bayer AB"}